Homocystinuria: Treatment With N-Acetylcysteine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-11-30

Study Completion Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is determine if oral N-acetylcysteine is effective in lowering homocysteine in individuals with homocystinuria.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Homocysteine Metabolism in Homocystinuria

NCT00004356

Homocystinuria

COMPLETED

Homocysteine in Acute Coronary Syndrome

NCT05125419

Acute Coronary Syndrome

COMPLETED

Homocysteine Study (HOST)

NCT00032435

End Stage Renal Disease Renal Failure

COMPLETED PHASE3

Effects of Homocysteine in Myocardial Infarction Patients in a Tertiary Care Hospital of Pakistan

NCT05011032

Homocystine; Metabolic Disorder

WITHDRAWN NA

Effects of Supplementation of Compound Nutrients on Plasma Homocysteine in Chinese Adults With Hyperhomocysteinemia

NCT03720249

Hyperhomocysteinemia

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Homocystinuria (MIM 236200) due to CBS deficiency is the most common inborn error of sulfur amino acid metabolism with severe clinical manifestations. We propose:

1. An open-label pilot study of N-acetylcysteine (NAC) to lower plasma homocysteine levels in those that have not responded to conventional treatment which includes betaine (Cystadane®, Orphan Medical Inc.), which while lowering Hcy levels does not normalize it, and is very expensive. There are no known contraindications to NAC used for nutritional supplementation and it is relatively inexpensive.

Oral NAC has reduced total plasma homocysteine in healthy subjects in a dose-dependent fashion.
2. Measurement of flow-mediated vasodilation of the brachial artery (endothelial function) in response to NAC treatment. Endothelial dysfunction is a precursor of atherogenesis.
3. Sequencing the CBS gene in these individuals in order to identify novel mutations causing homocystinuria and identify polymorphisms in other genes that may affect response to treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Homocystinuria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

N-acetylcysteine

Intervention Type DRUG

2 g p.o. BID x 60 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

N-acetylcysteine

2 g p.o. BID x 60 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NAC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Homocystinuria (lens dislocation and hyperhomocysteinemia)
* Age ≥ 18 (the age of majority in Canada)

Exclusion Criteria

* Nursing mothers or pregnant women
* Chronic liver disease
* Taking nitrates
* Cystine stone formers
* History of active peptic ulcer disease
* Subjects receiving carbamazepine and metoclopramide
* Use of other products containing cysteine or N-acetylcysteine (e.g. nebulized NAC, cysteine supplements, methionine restriction)
* Hypersensitivity to any ingredient in the study product
* Clinically significant, abnormal laboratory test on screening (Visit 2)

Other Criteria:

* Women of child-bearing capacity must be using an acceptable method of birth control and have a negative pregnancy test before being enrolled

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No